To access the full text documents, please follow this link: http://hdl.handle.net/2445/121168
dc.contributor.author | Santacruz, Rodrigo |
---|---|
dc.contributor.author | Villamor i Casas, Neus |
dc.contributor.author | Aymerich Gregorio, Marta |
dc.contributor.author | Martínez Trillos, Alejandra |
dc.contributor.author | López, Cristina |
dc.contributor.author | Navarro López, Alba |
dc.contributor.author | Rozman, María |
dc.contributor.author | Beà Bobet, Sílvia M. |
dc.contributor.author | Royo Moreno, Cristina |
dc.contributor.author | Cazorla, Maite |
dc.contributor.author | Colomer Pujol, Dolors |
dc.contributor.author | Giné Soca, Eva |
dc.contributor.author | Pinyol, Magda |
dc.contributor.author | Puente, Xose S. |
dc.contributor.author | López-Otin, Carlos |
dc.contributor.author | Campo Güerri, Elias |
dc.contributor.author | López Guillermo, Armando |
dc.contributor.author | Delgado, Julio (Delgado González) |
dc.date | 2018-03-27T15:27:41Z |
dc.date | 2018-03-27T15:27:41Z |
dc.date | 2014-05 |
dc.date | 2018-03-27T15:27:41Z |
dc.identifier | 0390-6078 |
dc.identifier | 646638 |
dc.identifier | 24700492 |
dc.identifier.uri | http://hdl.handle.net/2445/121168 |
dc.description | A proportion of patients with chronic lymphocytic leukemia achieve a minimal residual disease negative status after therapy. We retrospectively evaluated the impact of minimal residual disease on the outcome of 255 consecutive patients receiving any front-line therapy in the context of a detailed prognostic evaluation, including assessment of IGHV, TP53, NOTCH1 and SF3B1 mutations. The median follow-up was 73 months (range, 2-202) from disease evaluation. The median treatment-free survival durations for patients achieving a complete response without or with minimal residual disease, a partial response and no response were 76, 40, 11 and 11 months, respectively (P<0.001). Multivariate analysis revealed that three variables had a significant impact on treatment-free survival: minimal residual disease (P<0.001), IGHV status (P<0.001) and β2-microglobulin levels (P=0.012). With regards to overall survival, factors predictive of an unfavorable outcome were minimal residual disease positivity (P=0.014), together with advanced age (P<0.001), unmutated IGHV status (P=0.001), TP53 mutations (P<0.001) and elevated levels of β2-microglobulin (P=0.003). In conclusion, for patients requiring front-line therapy, achievement of minimal residual disease negativity is associated with significantly prolonged treatment-free and overall survival irrespective of other prognostic markers or treatment administered. |
dc.format | 8 p. |
dc.format | application/pdf |
dc.language | eng |
dc.publisher | Ferrata Storti Foundation |
dc.relation | Reproducció del document publicat a: https://doi.org/10.3324/haematol.2013.099796 |
dc.relation | Haematologica, 2014, vol. 99, num. 5, p. 873-880 |
dc.relation | https://doi.org/10.3324/haematol.2013.099796 |
dc.rights | (c) Ferrata Storti Foundation, 2014 |
dc.rights | info:eu-repo/semantics/openAccess |
dc.subject | Leucèmia limfocítica crònica |
dc.subject | Biologia molecular |
dc.subject | Limfomes |
dc.subject | Chronic lymphocytic leukemia |
dc.subject | Molecular biology |
dc.subject | Lymphomas |
dc.title | The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy. |
dc.type | info:eu-repo/semantics/article |
dc.type | info:eu-repo/semantics/publishedVersion |